139 related articles for article (PubMed ID: 33414491)
1. p21-activated kinases as viable therapeutic targets for the treatment of high-risk Ewing sarcoma.
Qasim SL; Sierra L; Shuck R; Kurenbekova L; Patel TD; Rajapakshe K; Wulff J; Nakahata K; Kim HR; Landesman Y; Unger TJ; Coarfa C; Yustein JT
Oncogene; 2021 Feb; 40(6):1176-1190. PubMed ID: 33414491
[TBL] [Abstract][Full Text] [Related]
2. Targeting PAK4 Inhibits Ras-Mediated Signaling and Multiple Oncogenic Pathways in High-Risk Rhabdomyosarcoma.
Dasgupta A; Sierra L; Tsang SV; Kurenbekova L; Patel T; Rajapakse K; Shuck RL; Rainusso N; Landesman Y; Unger T; Coarfa C; Yustein JT
Cancer Res; 2021 Jan; 81(1):199-212. PubMed ID: 33168646
[TBL] [Abstract][Full Text] [Related]
3. Dual and Specific Inhibition of NAMPT and PAK4 By KPT-9274 Decreases Kidney Cancer Growth.
Abu Aboud O; Chen CH; Senapedis W; Baloglu E; Argueta C; Weiss RH
Mol Cancer Ther; 2016 Sep; 15(9):2119-29. PubMed ID: 27390344
[TBL] [Abstract][Full Text] [Related]
4. miR-130b directly targets ARHGAP1 to drive activation of a metastatic CDC42-PAK1-AP1 positive feedback loop in Ewing sarcoma.
Satterfield L; Shuck R; Kurenbekova L; Allen-Rhoades W; Edwards D; Huang S; Rajapakshe K; Coarfa C; Donehower LA; Yustein JT
Int J Cancer; 2017 Nov; 141(10):2062-2075. PubMed ID: 28748534
[TBL] [Abstract][Full Text] [Related]
5. Dual PAK4-NAMPT Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldenström Macroglobulinemia.
Li N; Lopez MA; Linares M; Kumar S; Oliva S; Martinez-Lopez J; Xu L; Xu Y; Perini T; Senapedis W; Baloglu E; Shammas MA; Hunter Z; Anderson KC; Treon SP; Munshi NC; Fulciniti M
Clin Cancer Res; 2019 Jan; 25(1):369-377. PubMed ID: 30206161
[TBL] [Abstract][Full Text] [Related]
6. PAK4-NAMPT Dual Inhibition Sensitizes Pancreatic Neuroendocrine Tumors to Everolimus.
Mpilla GB; Uddin MH; Al-Hallak MN; Aboukameel A; Li Y; Kim SH; Beydoun R; Dyson G; Baloglu E; Senapedis WT; Landesman Y; Wagner KU; Viola NT; El-Rayes BF; Philip PA; Mohammad RM; Azmi AS
Mol Cancer Ther; 2021 Oct; 20(10):1836-1845. PubMed ID: 34253597
[TBL] [Abstract][Full Text] [Related]
7. A novel orally bioavailable compound KPT-9274 inhibits PAK4, and blocks triple negative breast cancer tumor growth.
Rane C; Senapedis W; Baloglu E; Landesman Y; Crochiere M; Das-Gupta S; Minden A
Sci Rep; 2017 Feb; 7():42555. PubMed ID: 28198380
[TBL] [Abstract][Full Text] [Related]
8. Abemaciclib Is Active in Preclinical Models of Ewing Sarcoma via Multipronged Regulation of Cell Cycle, DNA Methylation, and Interferon Pathway Signaling.
Dowless M; Lowery CD; Shackleford T; Renschler M; Stephens J; Flack R; Blosser W; Gupta S; Stewart J; Webster Y; Dempsey J; VanWye AB; Ebert P; Iversen P; Olsen JB; Gong X; Buchanan S; Houghton P; Stancato L
Clin Cancer Res; 2018 Dec; 24(23):6028-6039. PubMed ID: 30131386
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of neuroblastoma proliferation by PF-3758309, a small-molecule inhibitor that targets p21-activated kinase 4.
Li Z; Li X; Xu L; Tao Y; Yang C; Chen X; Fang F; Wu Y; Ding X; Zhao H; Li M; Qian G; Xu Y; Ren J; Du W; Wang J; Lu J; Hu S; Pan J
Oncol Rep; 2017 Nov; 38(5):2705-2716. PubMed ID: 29048629
[TBL] [Abstract][Full Text] [Related]
10. PAK1 and PAK4 as therapeutic targets for Ewing sarcoma: a commentary.
Parks SE; Yustein JT
J Cancer Biol; 2021; 2(4):94-97. PubMed ID: 36594908
[TBL] [Abstract][Full Text] [Related]
11. Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma.
Aboukameel A; Muqbil I; Senapedis W; Baloglu E; Landesman Y; Shacham S; Kauffman M; Philip PA; Mohammad RM; Azmi AS
Mol Cancer Ther; 2017 Jan; 16(1):76-87. PubMed ID: 28062705
[TBL] [Abstract][Full Text] [Related]
12. Targeted inhibition of histone deacetylase leads to suppression of Ewing sarcoma tumor growth through an unappreciated EWS-FLI1/HDAC3/HSP90 signaling axis.
Ma Y; Baltezor M; Rajewski L; Crow J; Samuel G; Staggs VS; Chastain KM; Toretsky JA; Weir SJ; Godwin AK
J Mol Med (Berl); 2019 Jul; 97(7):957-972. PubMed ID: 31025088
[TBL] [Abstract][Full Text] [Related]
13. Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth.
Murray BW; Guo C; Piraino J; Westwick JK; Zhang C; Lamerdin J; Dagostino E; Knighton D; Loi CM; Zager M; Kraynov E; Popoff I; Christensen JG; Martinez R; Kephart SE; Marakovits J; Karlicek S; Bergqvist S; Smeal T
Proc Natl Acad Sci U S A; 2010 May; 107(20):9446-51. PubMed ID: 20439741
[TBL] [Abstract][Full Text] [Related]
14. SRC Family Kinase Inhibition in Ewing Sarcoma Cells Induces p38 MAP Kinase-Mediated Cytotoxicity and Reduces Cell Migration.
Indovina P; Casini N; Forte IM; Garofano T; Cesari D; Iannuzzi CA; Del Porro L; Pentimalli F; Napoliello L; Boffo S; Schenone S; Botta M; Giordano A
J Cell Physiol; 2017 Jan; 232(1):129-35. PubMed ID: 27037775
[TBL] [Abstract][Full Text] [Related]
15. KPT-9274, an Inhibitor of PAK4 and NAMPT, Leads to Downregulation of mTORC2 in Triple Negative Breast Cancer Cells.
Cordover E; Wei J; Patel C; Shan NL; Gionco J; Sargsyan D; Wu R; Cai L; Kong AN; Jacinto E; Minden A
Chem Res Toxicol; 2020 Feb; 33(2):482-491. PubMed ID: 31876149
[TBL] [Abstract][Full Text] [Related]
16. Anticystogenic activity of a small molecule PAK4 inhibitor may be a novel treatment for autosomal dominant polycystic kidney disease.
Hwang VJ; Zhou X; Chen X; Trott J; Abu Aboud O; Shim K; Dionne LK; Chmiel KJ; Senapedis W; Baloglu E; Mahjoub MR; Li X; Weiss RH
Kidney Int; 2017 Oct; 92(4):922-933. PubMed ID: 28545714
[TBL] [Abstract][Full Text] [Related]
17. Combined LIM kinase 1 and p21-Activated kinase 4 inhibitor treatment exhibits potent preclinical antitumor efficacy in breast cancer.
Zhao CC; Zhan MN; Liu WT; Jiao Y; Zhang YY; Lei Y; Zhang TT; Zhang CJ; Du YY; Gu KS; Wei W
Cancer Lett; 2020 Nov; 493():120-127. PubMed ID: 32829006
[TBL] [Abstract][Full Text] [Related]
18. PAK1 overexpression promotes cell proliferation in cutaneous T cell lymphoma via suppression of PUMA and p21.
Wang Y; Gu X; Li W; Zhang Q; Zhang C
J Dermatol Sci; 2018 Apr; 90(1):60-67. PubMed ID: 29307600
[TBL] [Abstract][Full Text] [Related]
19. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
[TBL] [Abstract][Full Text] [Related]
20. Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma.
Fulciniti M; Martinez-Lopez J; Senapedis W; Oliva S; Lakshmi Bandi R; Amodio N; Xu Y; Szalat R; Gulla A; Samur MK; Roccaro A; Linares M; Cea M; Baloglu E; Argueta C; Landesman Y; Shacham S; Liu S; Schenone M; Wu SL; Karger B; Prabhala R; Anderson KC; Munshi NC
Blood; 2017 Apr; 129(16):2233-2245. PubMed ID: 28096095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
